Paul Workman (scientist)
| Paul Workman | |
|---|---|
Paul Workman at the Royal Society admissions day in London, July 2016
|
|
| Born |
30 March 1952 Workington, Cumbria, England |
| Nationality | British |
| Institutions | |
| Alma mater |
|
| Thesis | Studies on some enzyme-activated anti-tumour agents (1976) |
| Known for | Cancer drugs |
| Notable awards | |
|
Website www |
|
Paul Workman, FRS, FRSC, FMedSci (born 30 March 1952) is a British scientist noted for his work on the discovery and development of new cancer drugs. As of 2016[update] Workman is Harrap Professor of Pharmacology and Therapeutics and Chief Executive of The Institute of Cancer Research, London (ICR), previous Head of its Division of Cancer Therapeutics and Director of its Cancer Research UK Cancer Therapeutics Unit (1997 – Jan 2016).
Workman was born on 30 March 1952 in Workington, Cumbria, England. He was educated at Workington County Grammar School, Cumbria, and completed his Bachelor of Science in Biochemistry at the University of Leicester and his PhD in Cancer Pharmacology at the University of Leeds. He later received an Honorary DSc from the University of Leicester, in 2009.
The early part of his career (1976–90) was spent establishing and leading the Pharmacology and New Drug Development Laboratory at the Medical Research Council's Clinical Oncology Unit at the University of Cambridge, where he developed new treatments to exploit hypoxic cells in solid tumours and elucidated the enzymes involved in the activation of hypoxia-targeted drugs.
In 1990 Workman spent a sabbatical period in the Department of Therapeutic Radiology, Stanford University and SRI International, California, USA where he continued his work on tumour hypoxia funded by a Fellowship from what was then the International Union Against Cancer. In collaboration with scientists at SRI International he was co-inventor of an imaging agent to detect tumour hypoxia., for which he later demonstrated proof of concept in the clinic.
...
Wikipedia